Up-regulation of serine protease inhibitor Kazal type 1 expression in human lung adenocarcinoma and promotion of proliferation of cancer cells&nbsp;

LU Chang-chang HUANG Yan-yan XU Li-yun HE Jian-ying QIU lei LE Han-bo*

doi:10.16098/j.issn.0529-1356.2019.02.009

PDF(10472 KB)

Acta Anatomica Sinica ›› 2019, Vol. 50 ›› Issue (2) : 192-200. DOI: 10.16098/j.issn.0529-1356.2019.02.009

Up-regulation of serine protease inhibitor Kazal type 1 expression in human lung adenocarcinoma and promotion of proliferation of cancer cells

LU Chang-chang¹ HUANG Yan-yan¹ XU Li-yun¹ HE Jian-ying¹ QIU lei² LE Han-bo^3*

Author information +

History +

Abstract

Objective To explore the relationship between serine protease inhibitor Kazal type 1(SPINK1) expression and survival time of lung adenocarcinoma (LAC) and its effect on the growth of LAC cells. Methods The SPINK1 expressions in 285 cases of lung adenocarcinoma tissues and adjacent tissues were detected by Real-time PCR and immunohistochemical staining. The relationship between SPINK1 expression and clinicopathological features and prognosis of lung adenocarcinoma was analyzed. Human LAC cells were treated with lentivirus vector with SPINK1 or SPINK1 siRNA. Green fluorescent protein(GFP) expression was observed under microscope. SPINK1 expression was detected by enzyme-linked immunosorbent assay (ELISA) or Real-time PCR. The growth of LAC cells was evaluated by cell count and colony formation assay. Results The levels of SPINK1 mRNA and protein level in lung adenocarcinoma were up-regulated (P<0.0001). The overall survival time in the group of SPINK1 high expression was shorter than that of SPINK1 low expression (50.0 months vs 64.5 months, P<0.001). In SPINK1 overexpression group, SPINK1 protein was up-regulated in the cultures of LAC cells (P<0.05), and the ability of proliferation and colony formation was up-regulated (P<0.05). In SPINK1 knockdown group, SPINK1 mRNA was down-regulated in LAC cells (P<0.05), and the ability of proliferation was decreased (P<0.05). Conclusion High expression of SPINK1 in lung adenocarcinoma suggests poor prognosis. SPINK1 promotes the proliferation of LAC cells.

Key words

Lung adenocarcinoma / Serine protease inhibitor Kazal type 1 / Cell proliferation / Real-time PCR / Human

Cite this article

EndNote

Ris (Procite)

Bibtex

Download Citations

LU Chang-chang HUANG Yan-yan XU Li-yun HE Jian-ying QIU lei LE Han-bo. Up-regulation of serine protease inhibitor Kazal type 1 expression in human lung adenocarcinoma and promotion of proliferation of cancer cells [J]. Acta Anatomica Sinica. 2019, 50(2): 192-200 https://doi.org/10.16098/j.issn.0529-1356.2019.02.009

References

［1］ Jemal A, Bray F, Center MM, et al. Global cancer statistics[J]. CA Cancer J Clin, 2011, 61(2):69-90.

［2］ Ohmuraya M, Ozaki N, Hirota M, et al. Serine Proteaae inhibitor kazal type1 (SPINK1):Beyond the trypsin inhibitor ［J］. Curr Enzyme Inhib, 2009, 5(2):110-116.

［3］ Itkonen O, Stenmam UH. TATI as a biomarker ［J］. Clin Chim Acta, 2014, 20(421):260-269.

［4］ Lippolis G, Edsjo A, Stenmam UH, et al. A high-density tissue microarray from patients with clinically localized prostate cancer reveals ERG and TATI exclusivity in tumor cells ［J］. Prostate Cancer Prostatic Dis, 2013, 16(2):145-150.

［5］ Grupp K, Diebel F, Sirma H, et al. SPINK1 expression is tightly linked to 6q15-and 5q21-deleted RRG-fusion negative prostat cancers but unrelated to PSA recurrence ［J］. Prostate, 2013,73(15):1690-1698.

［6］ Soon WW, Miller LD, Black MA, et al. Combined genomic and phenotype screening reveals secretory factor SPINK1 as an invasion and survival factor associated with patient prognosis in breast cancer ［J］. EMBO Mol Med, 2011,3(8):451-464.

［7］ R?s?nen K, Dang KX, Mustonen H, et al. MAPK inhibitors induce serine peptidase inhibitor Kazal type 1 (SPINK1) secretion in BRAF V600E mutant colorectal adenocarcinoma［J］. Mol Oncol, 2018, 12(2):224-238.

［8］ Zhang X, Yin X, Shen P, et al. The association between SPINK1 and clinical outcomes in patients with prostate cancer: a systematic review and meta-analysis［J］. Onco Targets Ther, 2017, 10:3123-3130.

［9］ Lee YC, Pan HW, Peng SY, et al. Overexpression of tumour-associated trypsin inhibitor (TATI) enhances tumour growth and is associated with portal vein invasion, early recurrence and a stage-independent prognostic factor of hepatocellular carcinoma［J］. Eur J Cancer, 2007, 43(4):736-744.

［10］ Ozaki N, Ohmuraya M, Hirota M, et al. Serine protease inhibitor Kazal type 1 promotes proliferation of pancreatic cancer cells throuth the epidermal growth factor receptor ［J］. Mol Cancer Res, 2009, 7(9):1572-1581.

［11］ Chen YT, Tsao SC, Yuan SSF, et al. Serine protease inhibitor kazal type 1 (spink1) promotes proliferation of colorectal cancer through the epidermal growth factor as a prognostic marker［J］. Pathol Oncol Res Por, 2015, 21(4):1-8.

［12］ Mehner C, Oberg AL, Kalli KR, et al. Serine protease inhibitor Kazal type 1 (SPINK1) drives proliferation and anoikis resistance in a subset of ovarian cancers ［J］. Oncotarget, 2015, 6(34): 35737-35754.

［13］ Hedstr?m J, Haglund C, Leinonen J, et al. Trypsinogen-1,-2 and tumour-associated trypsin-inhibitor in bile and biliary tract tissues from patients with biliary tract diseases and pancreatic carcinomas［J］. Scand J Clin Lab Invest, 2001, 61(2):111-118.

［14］ R?ty S, Sand J, Laukkarinen J, et al. Cyst fluid SPINK1 may help to differentiate benign and potentially malignant cystic pancreatic lesions［J］. Pancreatology, 2013, 13(5):530-533.

［15］ Bohe H, Bohe M, Lindstrm C, et al. Immunoreactive pancreatic secretory trypsin inhibitor in normal, inflammatory and neoplastic gallbladders［J］. Gastroenterol Jpn, 1991, 26(1):95-98.

［16］ Tonouchi A, Ohtsuka M, Ito H, et al. Relationship between pancreatic secretory trypsin inhibitor and early recurrence of intrahepatic cholangiocarcinoma following surgical resection［J］. Am J Gastroenterol, 2006, 101(7):1601-1610.

［17］ Hotakainen K, Bjartell A, Sankila A, et al. Differential expression of trypsinogen and tumorassociated trypsin inhibitor (TATI) in bladder cancer［J］. Inte J Oncol, 2006, 28(1):95-101.

［18］ Patschan O, Shariat SF, Chade DC, et al. Association of tumor-associated trypsin inhibitor (TATI) expression with molecular markers, pathologic features and clinical outcomes of urothelial carcinoma of the urinary bladder［J］. World J Urol, 2012, 30(6):785-794.

［19］ Rink M, Park K, Volkmer BG. Loss of SPINK1 expression is associated with unfavorable outcomes in urothelial carcinoma of the bladder after radical cystectomy［J］. Urol Oncol, 2013, 31(8):1716-1724.

［20］ Kelloniemi E, Rintala E, Finne P, et al. Tumor-associated trypsin inhibitor as a prognostic factor during follow-up of bladder cancer［J］. Urology, 2003, 62(2):249-253.

［21］ Shek FH, Luo R, Lam BYH, et al. Serine peptidase inhibitor Kazal type 1 (SPINK1) as novel downstream effector of the cadherin-17/β-catenin axis in hepatocellular carcinoma［J］. Cell Oncol, 2017, 40(5):443-456.

［22］ Kemik O, Kemik A, Sümer A, et al. The relationship between serum tumor-associated trypsin inhibitor levels and clinicopathological parameters in patients with gastric cancer［J］. Eur Rev Med Pharmacol Sci, 2013, 17(21):2923-2928.

［23］ Herrmann D, J?ger L, Hein G, et al. Comparison of the prognostic value of a panel of tissue tumor markers and established clinicopathological factors in patients with gastric cancer［J］. Anticancer Res, 2008, 28(4C):2279-2287.

［24］ Lukkonen A, Lintula S, Von Boguslawski K, et al. Tumor‐associated trypsin inhibitor in normal and malignant renal tissue and in serum of renal‐cell carcinoma patients［J］. Int J Cancer, 1999, 83(4):486-490.

［25］ Ozaki N, Ohmuraya M, Ida S, et al. Serine protease inhibitor Kazal type 1 and epidermal growth factor receptor are expressed in pancreatic tubular adenocarcinoma, intraductal papillary mucinous neoplasm, and pancreatic intraepithelial neoplasia［J］. J Hepatobiliary Pancreati Sci, 2013, 20(6):620-627.

［26］ Tsuzuki S, Kokado Y, Satomi S, et al. Purification and identification of a binding protein for pancreatic secretory trypsin inhibitor: a novel role of the inhibitor as an anti-granzyme A［J］. Biochemi J, 2003, 372(Pt 1):227-233.

［27］ Niinobu T, Ogawa M, Murata A, et al. Identification and characterization of receptors specific for human pancreatic secretory trypsin inhibitor［J］. J Exp Med, 1990, 172(4):1133-1142.

［28］ Tomlins SA, Rhodes DR, Yu J, et al. The role of SPINK1 in ETS rearrangement-negative prostate cancers［J］. Cancer Cell, 2008, 13(6):519-528.

［29］ Gouyer Ⅴ, Fontaine D, Dumont P, et al. Autocrine induction of invasion and metastasis by tumor-associated trypsin inhibitor in human colon cancer cells［J］. Oncogene, 2008, 27(29):4024-4033.